Englert R, Beressem P, von Manteuffel E, Stafunsky M, Kramar M
Veitlipp 2, Gars am Inn, Germany.
Postgrad Med J. 1991;67 Suppl 5:S35-7.
This study compared the efficacy and safety of 8 weeks of open treatment with the dihydropyridine calcium antagonists amlodipine and nitrendipine in mild-to-moderate hypertension. Interim analysis of data from 74 patients (43 male, 31 female) showed that amlodipine normalized diastolic blood pressure (less than or equal to 90 mmHg) in 95% of patients compared with 83% of nitrendipine-treated patients. Nitrendipine produced a statistically significant increase in heart rate at 2 and 4 weeks of therapy but there was no significant change in heart rate in amlodipine-treated patients. Amlodipine-treated patients reported fewer adverse events (26%) than did the nitrendipine-treated group (47%), with two patients from the nitrendipine group discontinuing treatment due to treatment-related adverse events. Adverse events in the amlodipine-treated group were mild to moderate. The incidence of flushing was higher in nitrendipine-treated patients (25%) than in amlodipine-treated patients (10%). This relative difference in the incidence of vasodilator-related side effects is probably explained by the gradual onset of effect with amlodipine.
本研究比较了二氢吡啶类钙拮抗剂氨氯地平和尼群地平对轻至中度高血压患者进行8周开放治疗的疗效和安全性。对74例患者（43例男性，31例女性）的数据进行的中期分析显示，氨氯地平使95%的患者舒张压恢复正常（小于或等于90 mmHg），而尼群地平治疗的患者这一比例为83%。尼群地平在治疗2周和4周时使心率有统计学意义的增加，但氨氯地平治疗的患者心率无显著变化。氨氯地平治疗的患者报告的不良事件（26%）少于尼群地平治疗组（47%），尼群地平组有2例患者因治疗相关不良事件而停药。氨氯地平治疗组的不良事件为轻至中度。尼群地平治疗的患者潮红发生率（25%）高于氨氯地平治疗的患者（10%）。血管扩张剂相关副作用发生率的这种相对差异可能是由于氨氯地平的作用起效较缓慢。
